Cargando…
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
In clinical practice natalizumab is typically used in patients who have experienced breakthrough disease during treatment with interferon beta (IFNβ) or glatiramer acetate. In these patients it is important to reduce disease activity as quickly as possible. In a phase II study, differences between n...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642366/ https://www.ncbi.nlm.nih.gov/pubmed/23292204 http://dx.doi.org/10.1007/s00415-012-6809-7 |